What Is IPL?
While there are an overwhelming number of clinically administered treatment options for those looking to refine their skin’s appearance, only one breakthrough technology can accomplish all the essential objectives of cosmetic dermatology: Intense Pulsed Light (IPL™).
Pioneered and patented by Lumenis Inc. (NASDAQ: LUME), IPL™ is the world’s only non-ablative, full-face treatment technology available to address all the signs of photoaging with remarkably smooth, natural-looking results and no downtime – a crucial consideration in today’s fast-paced world.
Administered using a process called photorejuvenation, IPL™ custom-treats the tone and texture of the entire face rather than a single isolated area or imperfection, imparting an overall brighter, more youthful appearance. It is also ideal for the neck, chest, arms and hands.
Age And Sun-induced Skin Conditions
IPL™ technology treats the widest spectrum of age- and sun-induced skin conditions, including:
· Redness (rosacea/erythema)· Telangiectasias (spider veins/broken capillaries/spider veins or purple/blue veins on face)
· Fine lines/rhytides· Brown spots (hyperpigmentation/melasma)
· Sun damage (sun-induced freckles)· Non-facial photoaging
It can also be used for:
•Age spots•Liver spots
•Fine lines and wrinkles•Facial flushing
•Broken capillaries•Hemangiomas (red, purple, or blue birthmarks formed by blood vessels)
•Port wine stains•Tattoos
•Varicose veins•Flat Birthmarks
•Hypopigmentation (pale spots)•Unwanted hair
Considered the most versatile of all cosmetic treatments, IPL™ allows patients to return immediately to routine activities, produces gradual, natural-looking progress, and can treat several skin conditions simultaneously.
IPL™: THE POWER OF LIGHT
IPL™ technology was introduced to the field of dermatology and patented in 1996 by Lumenis Inc.
Prior to this ground-breaking discovery, dermatologists relied on either less effective procedures or else more invasive, risky and time-consuming procedures to treat visible aging, including microdermabrasion and chemical peels.
Lumenis’ revolutionary IPL™ technology quickly and definitively developed as the most sought-after solution for those demanding superior, long-lasting improvement without the discomfort, extended recovery time or pronounced risks associated with more traditional procedures.
Lumenis also coined the word photorejuvenation, defined as the skin treatment that uses IPL™ technology to refresh and revitalize photoaged skin. Today, photorejuvenation is an established, highly regarded term in medical/dermatological vernacular.
IPL™ devices emit customized, intense pulses of light (between 500 to 1200 nm) into the deeper, dermal section of skin, where blood vessels, pigment cells and collagen are found, without damaging or removing the outer epidermal layers.
Using the IPL™ spectrum appropriate for the clinical objective, light energy is first transformed into heat energy and is absorbed by the target tissue. During the treatment, the source of discoloration in the skin tissue – such as hemoglobin or pigment – is painlessly destroyed without damaging surrounding tissue.
On average, five full treatments over a period of four months are recommended.
IPL™ VERSUS LASERS
Unlike lasers, which utilize monochromatic, coherent light sources, IPL™ is characterized by its ability to use non-coherent, broad-spectrum light with a divergent approach. Other differences include:
· The single wavelength of lasers (monochromaticity) means it will only absorb at a specified depth, while the multiple wavelengths of IPL™ can emit several wavelengths of the electromagnetic spectrum, allowing for synchronized treatment of different skin conditions.
· There is evidence that IPL™ promotes improved texture and tone.
COMBINATION IPL™ SOLUTIONS
IPL™ skin treatments for photorejuvenation addresses a broad portfolio of skin-related concerns, from hyperpigmentation to age lines to vascular lesions.
When coupled with innovative Nd:YAG laser technology, the treatment options are almost limitless. Lumenis integrates IPL™ with multiple synchronized, pulsed high-energy Nd:YAG laser in a single, dedicated system to successfully address more complex skin concerns, including deeper superficial veins, prominent wrinkles, hair removal, intricate telangiectatic matting and hemosiderin stains.
With this specialized approach, the near-infrared Nd:YAG (1064 nm) component obtains ideal penetration into the skin for treating deeper, bluer vessels, while the shorter IPL™ wavelengths are optimal for eliminating shallower veins. The Lumenis VascuLight and IPL™ Quantum DL systems combine the features and benefits of both IPL™ and laser technologies.
IPL™ Plus Botox
IPL™ is also an ideal complement to Botox, which was cleared by the Food and Drug Administration in 2002 for treating glabellar lines (the wrinkles between the eyebrows). Botox pioneer Dr. Jean Carruthers called the use of Botox with IPL™ as ‘complementary’ for several reasons:
· IPL™ helps prime the canvas of the face for Botox; it smoothes away brown and red discolorations while improving skin’s general texture and tone.· While Botox’s effects take time to appear, IPL™ effects begin quickly, giving patients near-term, tangible results.
· Botox and IPL™ treatments can be performed during the same office visit, thus minimizing time investment.
For specialized aesthetic applications, IPL™ can be combined with other aesthetic programs such as fillers (e.g., Restylane, Perlane) and other forms of cosmetic surgery depending on the patient’s skin condition and desired results. It is often used with microdermabrasion and chemical peels for those desiring more pronounced results. Because of its gentler full-face approach, IPL™ often helps smooth and polish these more invasive, area-specific procedures for a softer, more radiant overall appearance.
Lumenis develops, manufactures and markets state-of-the-art proprietary laser and Intense Pulsed Light (IPL™) devices. Its systems are used in a variety of aesthetic, ophthalmic, surgical and dental applications, including hair removal, non-invasive treatment of vascular lesions and pigmented lesions, acne, psoriasis, open angle glaucoma, secondary cataracts, age-related macular degeneration, urinary lithotripsy, benign prostatic hyperplasia, as well as ENT, gynecology, neurosurgery and dentistry. For more information about the Company and its products, log on to www.lumenis.com.The statements in this press release that are not historical facts are forward-looking statements, which are subject to risks and uncertainties. The Company’s actual results could differ materially from those anticipated in the forward-looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company’s products, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company’s international operations and the Company’s ability to integrate its operations with those of acquired businesses; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.